about
Postoperative tamoxifen for ductal carcinoma in situPredictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signaturesPatterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer.Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspectiveProgress in adjuvant chemotherapy for breast cancer: an overviewSex hormones, hormonal interventions, and gastric cancer risk: a meta-analysisImpact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body StudyThe properties of high-dimensional data spaces: implications for exploring gene and protein expression data.Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER statusNode-positive Breast Cancer: Which Are the Best Chemotherapy Regimens?Tracking progesterone receptor-mediated actions in breast cancerExtending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer.Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy.Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report.Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.Nanotamoxifen Delivery System: Toxicity Assessment After Oral Administration and Biodistribution Study After Intravenous Delivery of Radiolabeled Nanotamoxifen.Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.Medication use by early-stage breast cancer survivors: a 1-year longitudinal study.Factors predicting late recurrence for estrogen receptor-positive breast cancerERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer.The patient's perspectiveDo all patients with breast cancer require systemic adjuvant therapy?Optimal duration of adjuvant endocrine therapy: how to apply the newest data.Vinorelbine-induced regression of a choroidal metastasis from primary breast carcinoma.
P2860
Q24198028-BC634198-F992-4ED3-9C80-38A9294D044EQ24812541-61ADF427-F316-4426-8A22-B73E35B22B9DQ25257326-E511305A-341F-4E07-A63A-E8691C8990AAQ26752834-606ABC03-2EFD-4F4E-AF2E-FCF29CD0C5E7Q26798078-41F7FE44-FC46-4096-AB77-3D2C9ED420D3Q26823102-D366586C-A694-44CA-95CD-ABF8AF2E6E0BQ30758966-6A88A869-CEB6-4299-967C-02BACAB3C151Q31140694-D70A0A1D-61EB-46E2-ACF0-408BC317CF37Q33769803-99432539-BB6D-4D3A-92BD-B62B3CE9DD52Q34284278-092A2990-1F24-44E9-A72D-8D1D53F5FEB0Q34388848-365EE2A6-9A83-4735-8A11-91D198C4C53EQ34529725-B32B04B5-B64F-4497-931F-DABAB67D8637Q35006809-5C82520C-A173-4A80-A0B4-F4D2EDC0CA8EQ35051765-19307D7A-3108-479E-9452-E0882279CA05Q35653956-EF5CBAD2-5372-4040-AB2E-484B4F750829Q36015010-8A68C3AC-681F-48F3-BB6A-AD4F52F09896Q36033062-38863AC2-A6A4-424F-8397-BA295D61BCAEQ36508458-E8BAD11A-4121-4A9D-92AF-DDB79967FC28Q36578211-DB0F9B0C-7957-4B8C-B85D-7E15F71F1CDEQ36615005-D7C5F8B3-8427-44BD-ACAD-9FD76E9199DCQ37209554-EF4A564D-27FE-489B-AAD7-993DC4A4B78BQ37240697-F3648A8C-519E-46A5-B692-50F4BA4C48CEQ42384205-2AAEB1C8-DE79-452E-A492-8EB3E9C83E63Q42917969-60CB651B-BFEB-4D0C-8BC5-51DE3D44EF9DQ49177338-9684C27C-30FB-4120-8EF1-436EC2E11D67Q54978605-224901F2-FF57-4C57-A513-B05027752CB4
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Tamoxifen for early breast cancer.
@ast
Tamoxifen for early breast cancer.
@en
Tamoxifen for early breast cancer.
@nl
type
label
Tamoxifen for early breast cancer.
@ast
Tamoxifen for early breast cancer.
@en
Tamoxifen for early breast cancer.
@nl
prefLabel
Tamoxifen for early breast cancer.
@ast
Tamoxifen for early breast cancer.
@en
Tamoxifen for early breast cancer.
@nl
P1476
Tamoxifen for early breast cancer.
@en
P2093
Early Breast Cancer Trialists' Collaborative Group
P2860
P304
P356
10.1002/14651858.CD000486
P577
2001-01-01T00:00:00Z